Cargando…

Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis

OBJECTIVES: To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson's disease (PD). METHODS: Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Abhinaba, Das, Saibal, Behera, Sapan Kumar, Ramakrishnan, Kirubakaran, Selvarajan, Sandhiya, Kandasamy, Preeti, Nair, N Sreekumaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049416/
https://www.ncbi.nlm.nih.gov/pubmed/32211146
http://dx.doi.org/10.1155/2020/4853590
_version_ 1783502435110617088
author Ghosh, Abhinaba
Das, Saibal
Behera, Sapan Kumar
Ramakrishnan, Kirubakaran
Selvarajan, Sandhiya
Kandasamy, Preeti
Nair, N Sreekumaran
author_facet Ghosh, Abhinaba
Das, Saibal
Behera, Sapan Kumar
Ramakrishnan, Kirubakaran
Selvarajan, Sandhiya
Kandasamy, Preeti
Nair, N Sreekumaran
author_sort Ghosh, Abhinaba
collection PubMed
description OBJECTIVES: To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson's disease (PD). METHODS: Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included. Effect sizes (Cohen's d), the standardized mean difference in the scores of each cognitive domain, were compared using a random-effects model (MetaXL version 5.3). RESULTS: Three studies were included in the final analysis. For a change in complex attention in PD with mild cognitive impairment (MCI), the estimated effect size was small and nonsignificant (0.16 (95% CI: −0.09, 0.42), n = 42). For changes in executive function, perceptual-motor function, language, social cognition, and learning and memory, the estimated effect sizes were small and medium, but nonsignificant. A deteriorative trend in executive function was observed after atomoxetine treatment in PD with MCI. For a change in global cognitive function in PD without MCI, the estimated effect size was large and significant. CONCLUSION: In idiopathic PD with MCI, atomoxetine does not improve complex attention. Also, a deteriorative trend in the executive function was noted.
format Online
Article
Text
id pubmed-7049416
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-70494162020-03-24 Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis Ghosh, Abhinaba Das, Saibal Behera, Sapan Kumar Ramakrishnan, Kirubakaran Selvarajan, Sandhiya Kandasamy, Preeti Nair, N Sreekumaran Parkinsons Dis Research Article OBJECTIVES: To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson's disease (PD). METHODS: Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included. Effect sizes (Cohen's d), the standardized mean difference in the scores of each cognitive domain, were compared using a random-effects model (MetaXL version 5.3). RESULTS: Three studies were included in the final analysis. For a change in complex attention in PD with mild cognitive impairment (MCI), the estimated effect size was small and nonsignificant (0.16 (95% CI: −0.09, 0.42), n = 42). For changes in executive function, perceptual-motor function, language, social cognition, and learning and memory, the estimated effect sizes were small and medium, but nonsignificant. A deteriorative trend in executive function was observed after atomoxetine treatment in PD with MCI. For a change in global cognitive function in PD without MCI, the estimated effect size was large and significant. CONCLUSION: In idiopathic PD with MCI, atomoxetine does not improve complex attention. Also, a deteriorative trend in the executive function was noted. Hindawi 2020-02-17 /pmc/articles/PMC7049416/ /pubmed/32211146 http://dx.doi.org/10.1155/2020/4853590 Text en Copyright © 2020 Abhinaba Ghosh et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ghosh, Abhinaba
Das, Saibal
Behera, Sapan Kumar
Ramakrishnan, Kirubakaran
Selvarajan, Sandhiya
Kandasamy, Preeti
Nair, N Sreekumaran
Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
title Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
title_full Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
title_fullStr Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
title_full_unstemmed Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
title_short Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
title_sort atomoxetine does not improve complex attention in idiopathic parkinson's disease patients with cognitive deficits: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049416/
https://www.ncbi.nlm.nih.gov/pubmed/32211146
http://dx.doi.org/10.1155/2020/4853590
work_keys_str_mv AT ghoshabhinaba atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis
AT dassaibal atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis
AT beherasapankumar atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis
AT ramakrishnankirubakaran atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis
AT selvarajansandhiya atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis
AT kandasamypreeti atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis
AT nairnsreekumaran atomoxetinedoesnotimprovecomplexattentioninidiopathicparkinsonsdiseasepatientswithcognitivedeficitsametaanalysis